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Abstract
Background: The aim of the present study was to investigate the relationship
between mid-trimester ultrasound fetal liver length (FLL) and gestational
diabetes mellitus (GDM) in a high-risk population.
Methods: A prospective study was performed in 331 women with singleton
pregnancies who were at high risk of GDM and were undergoing a mid-
trimester ultrasound examination. The ultrasound scan at 23 weeks gestation
was followed by a 100-g oral glucose tolerance test (OGTT) at 24 weeks
gestation. Correlations between FLL and OGTT results at different time
points were tested. Receiver operating characteristic (ROC) analysis of FLL
as a potential prognostic factor for GDM was also performed.
Results: In GDM patients, there was a significant positive correlation
(P < 0.01) between FLL and OGTT glycemia immediately before and 60, 120,
and 180 min after glucose intake. Mean FLL in GDMwas significantly higher
than in healthy subjects (41.04 vs 31.09 mm, respectively; P < 0.001). When
tested as a potential prognostic factor for GDM, fetal liver measurements
showed excellent diagnostic performance. The ROC analysis established a
cut-off value of FLL of 39 mm for the prediction GDM, with sensitivity of
71.76%, specificity 97.56%, positive predictive value 91.0%, and negative pre-
dictive value 90.9%. The usefulness of FLL measurements was supported by
a high area under the ROC curve (90.5%).
Conclusion: In conclusion, there is a strong correlation between FLL and
OGTT results, with FLL possibly serving as a valid marker for the prediction
of GDM in high-risk populations.
Keywords: correlation, predictive value, sensitivity, specificity,
ultrasonography.
Significant findings of the study: In patients with gestational diabetes, there was a significant positive correlation
between fetal liver length (FLL) and blood glucose values during the oral glucose tolerance test (OGTT). The
usefulness of fetal liver length measurements was supported by high area under the receiver operating character-
istic curve.
What this study adds: FLL is strongly correlated with OGTT results and could serve as a valid marker for the
prediction of gestational diabetes in high-risk populations.
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Introduction
It is important to detect gestational diabetes mellitus
(GDM) because of its association with a high risk of
perinatal morbidity1 and increased risk of future diabetes
in the mother.2 To diagnose GDM, as an asymptomatic
entity, it must be screened for. The 50-g non-fasting 1-h
glucose challenge test (GCT) is the most widely imple-
mented screen used currently, despite its limitations,
which include the fact that it is time consuming, costly,
may be unpleasant, imposes a supraphysiological
glucose load that is unrelated to body weight, and lacks
reproducibility (in up to 24% of women). Furthermore,
lowering cut-off values in the 1-h GCT to enhance sen-
sitivity invariably jeopardizes specificity.3 Therefore,
alternative screening methods have been proposed to
increase the detection rates of GDM and to overcome
these shortcomings of the GCT. Some of the proposed
unconventional screening methods are based on ultra-
sound examinations, taking into account that these
examinations are routinely performed in most women
during the course of the pregnancy.4,5
Ultrasonography is a useful, readily available, non-
invasivemethod for the diagnosis and surveillance of fetal
conditions as part of the management of diabetic preg-
nancy.6 Furthermore, ultrasonography can be used to
detectGDM,4 aswell is a helpful guide for the initiation of
early therapeutic management for pregnancies compli-
cated by carbohydrate intolerance.7,8 Fetal growth is
evaluated throughout gestation by measuring various
fetal body dimensions. Some of these fetal body dimen-
sions, such as fetal liver length (FLL), could be considered
as ultrasoundparameters of glycemic control.4,5 Increased
glucose transfer from the diabetic mother to the fetus and
placenta results in fetal hyperglycemia and hyperinsuline-
mia, promoting growth of insulin-dependent tissues and
organs, such as the liver.9–12
Amid-trimester ultrasound scan is routinely performed
between 18 and 23 weeks gestation. This period of preg-
nancy is the most suitable for both adequate dating of the
pregnancy and the timely diagnosis of congenital anoma-
lies.13,14 During this scan, fetal hyperinsulinemia may be
suspected on the basis of increased fetal dimensions deter-
mined by the ultrasound examination. The abdominal
circumference reflects the growth of insulin-sensitive
organs, such as the fetal liver. Consequently, increased
abdominal circumference measurements suggest exces-
sive glycogen deposition in the liver secondary to raised
fetal insulin levels. Such an association between fetal
macrosomia and amniotic fluid insulin has already been
documented in the third trimester and at birth,15,16
The aim of the present study was to test correlations
between blood glucose levels during an oral glucose tol-
erance test (OGTT) with FLL evaluated the during mid-
trimester ultrasound examination, as well to assess the
value of these measurements in the screening of GDM in
a high-risk population of pregnant women.
Methods
This prospective study was approved by the Research
Ethics Committee of of Clinical Hospital Centre,
Zemun–Belgrade (Belgrade, Serbia; no. 1636) and by the
Research Ethics Committee of theMedical Faculty, Uni-
versity of Belgrade (no. 29/I-4). The study was performed
at the Clinic for Gynecology and Obstetrics, Clinical
Center of Serbia (Belgrade, Serbia) and at the Hospital
for Gynaecology and Obstetrics, Clinical Hospital
Centre, Zemun–Belgrade. The study population con-
sisted of pregnant women at high risk of GDMwho were
undergoing a mid-trimester ultrasound examination.
After informed consent had been obtained, a medical
and obstetric history was obtained for all women who
then underwent an obstetric ultrasound scan at 23 weeks
gestation, followed by a fasting 3-h 100-g OGTT at 24
weeks gestation. Women were suitable for inclusion in
the study if they had a singleton pregnancy, for which
pregnancy duration was determined on the basis of the
last certain menstrual period and confirmed by ultra-
sound measurement of fetal crown–rump length (at
10–12 weeks), and if they had risk factors for GDM
(body mass index [BMI] >30 kg/m2, multiparity, mater-
nal age >35 years, previous delivery of a macrosomic
child [>4000 g], polycystic ovary syndrome, family
history of diabetes). Women with a multiple pregnancy,
previous Cesarean sections, prepregnancy hypertension,
prepregnancy pathological OGTT values, type 1 or 2
diabetes, aged <18 years, maternal–fetal blood group
ABO incompatibility (titer >1: 30), on long-term medical
treatment that may have affected glucose metabolism,
and women with confirmed fetal abnormalities were
excluded from the study.
Ultrasound examinations and measurements of the
fetal liver were performed using either a variable convex
transducer (2–6 MHz) of the Xario SSA-660A ultra-
sound machine (Toshiba Medical Systems, Tokyo,
Japan) or the variable convex C2–61C transducer
(2–6 Hz) of the Accuvix V10 ultrasound machine
(Medison, Seoul, Korea). A sagittal or coronal section of
the fetal abdomen was used to measure liver length. The
tip of the right lobe of the liver was clearly identified and
liver length was measured from the dome of the right
hemidiaphragm to the tip of the right lobe.
The OGTT was performed using standard protocols.
Briefly, after a 12-h overnight fast, venous plasma
samples were collected to measure glucose levels at
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fasting and then 1, 2 and 3 h after administration of a
100-g glucose load. The oral glucose load was adminis-
tered chilled to minimize nausea, vomiting, and abdomi-
nal distension. Diagnoses of GDM were based on the
criteria of the American Diabetes Association.17
Because the ultrasound examinations preceded the
OGTT, all FLL measurements were made in a blinded
manner with regard to the results of the OGTT. Further-
more, the people responsible for recruiting patients to
the study, providing information about the study,
obtaining medical and obstetric histories, scheduling
ultrasound examinations and the OGTT (EG, EI, SD
and UB) were not involved in performing the ultrasound
examination. The physicians responsible for the ultra-
sound examinations (MP, MG, MK, TS, GK, BA and
JR) were not informed about the data obtained previ-
ously for the study participants, which means they were
blinded as to the risk group.
Statistical analysis
Data are presented as the mean ± SD. Categorical data
are presented as absolute numbers with percentages and
were analyzed using the Chi-squared test and Fisher’s
exact test. Continuous variables were analyzed using
Student’s t-test (normally distributed data) or theMann–
Whitney U-test (non-normally distributed data). Corre-
lation analyses were performed using the Pearson
product–moment correlation coefficient (normal distri-
bution) and Spearman’s rank correlation coefficient
(non-normal distribution). Binary logistic regression was
used to assess correlations between the FLL and GDM
with adjustment for educational level, parity, and BMI.
The ability of fetal liver measurements to discriminate
between positive and negative OGTT was described by
receiver operating characteristic (ROC) statistics using
different cut-off levels of FLL. The area under the curve
(AUC) was calculated and represents a quantitative
measure of the predictive value of fetal liver measure-
ments for a positive OGTT. Two-sided P < 0.05 was con-
sidered significant. The diagnostic efficiency of the
established cut-off value of FLL was evaluated for sen-
sitivity, specificity, positive predictive value, and negative
predictive value. All analyses were performed using SPSS
version 20 (SPSS, Chicago, IL, USA).
Sample size calculation
To show the expected sensitivity of ultrasound FLLmea-
surements (point estimate) ≥80% with a precision of 7%,
it was calculated that the study needed to include 124
subjects.
Results
Three hundred and fifty-seven of 366 eligible pregnant
women consented to participate in the study (between
January 2012 and January 2013). Of the 357 women who
consented to participate, nine were excluded because of
an intolerance to the oral glucose load and a further 17
were excluded because they failed to show up for the
OGTT, despite having provided consent and undergoing
the ultrasound examination. This left a final study popu-
lation of 331 women.
Descriptive characteristics of the study population are
given in Table 1. The prevalence of GDM in this high-
risk study population was 25.7%, with no significant dif-
ferences in the demographic characteristics between
subjects with and without GDM, except for BMI and
secundiparity (which were significantly higher in women
with GDM pregnancies) and a primary school level of
education (which was significantly higher in non-GDM
women; Table 1). Analysis of risk factors for GDM in
the study population, as well as in the GDM and non-
GDM subgroups, is presented in Table 2.
In GDM patients, there was a significant positive cor-
relation (P < 0.001) between FLL and blood glucose
levels during the OGTT (immediately before and 60,
120, and 180 min after glucose intake; R0 = +0.47,
R60 = +0.52, R120 = +0.58, R180 = 0.48). Results of FLL
measurements plotted against blood glucose levels imme-
diately before and 60, 120 and 180 min after the 100-g
glucose load OGTT are shown in Fig. 1. As indicated in
Fig. 1, FLL increased with increasing blood glucose
levels. Similar relationships between FLL and blood
glucose levels were detected at all time points in the
Table 1 Characteristics of the study participants and fetal liver mea-
surements
GDM Non-GDM P-value
No. participants 85 246 NA
Age (years) 28.8 ± 4.9 28.9 ± 5.9 >0.05
BMI (kg/m2) 29.7 ± 4.8 25.3 ± 3.9 <0.001
Parity
Nulliparity 27 (31.76%) 103 (41.87%) >0.05
Secundigravida 48 (56.47%) 109 (44.31%) <0.05
Tercigravida 8 (9.42%) 22 (8.94%) >0.05
Multiparity (≥4) 2 (2.35%) 12 (4.88%) >0.05
Education
Primary school level 5 (5.88%) 38 (15.45%) <0.05
High school level 64 (75.29%) 178 (72.36%) >0.05
University level 16 (18.83%) 30 (12.19%) >0.05
Data are given as the mean ± SD or as the number of subjects in
each group, with percentages in parentheses.
GDM, gestational diabetes mellitus.
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OGTT. Conversely, no such correlations were detected
in non-GDM subjects (P > 0.05; R0 = +0.13, R60 = +0.07,
R120 = +0.06, R180 = 0.04).
Univariate analysis revealed significant differences
between the GDM and non-GDM groups in BMI,
primary school education, and secundiparity. Correla-
tion analysis revealed that there was a significant corre-
lation between FLL and BMI only (r = 0.586; P < 0.001),
and not between FLL and either primary school educa-
tional level or parity.
Table 2 Prevalence of risk factors in the study group and subgroups
Study group GDM subgroup Non-GDM subgroup
No. subjects 331 (100%) 85 (100%) 246 (100%)
Cumulative no. risk factors*
One 196 (59.21%) 31 (36.47%) 165 (67.07%)
Two 114 (34.44%) 34 (40.00%) 80 (32.52%)
Three or more 21 (6.35%) 20 (23.53%) 1 (0.41%)
Type of risk factor†
BMI >30 kg/m2 81 (24.47%) 45 (52.94%) 36 (14.63%)
Multiparity 14 (4.23%) 2 (2.35%) 12 (4.88%)
Maternal age >35 years 85 (25.68%) 25 (29.41%) 59 (23.98%)
Delivery of macrosomic baby 101 (30.51%) 29 (34.18%) 73 (29.67%)
Polycystic ovary syndrome 65 (19.64%) 19 (22.35%) 46 (18.69%)
Family history of diabetes 143 (43.20%) 39 (45.88%) 104 (42.28%)
No. identified risk factors 489 159 330
Mean no. risk factors per person 1.48 1.87 1.34
*Data show the number of subjects in each group, with percentages in parentheses.
†Data show the number of subjects in each group with the risk factor, with the prevalence of the risk factors in each group or subgroup given
in parentheses.
GDM, gestational diabetes mellitus; BMI, body mass index.
Figure 1 Fetal liver length (determined by ultrasound examination at 23 weeks gestation) plotted against blood glucose levels (a) immediately
before and (b) 60, (c) 120 and (d) 180 min after a 100-g glucose load as part of an oral glucose tolerance test performed at 24 weeks gestation.
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Amultivariate logistic regression model was created in
three steps. In the first step, only liver length was used as
an independent variable, with GDM as the dependent
variable. A significant associationwas confirmed between
FLL andGDM(odds ratio [OR] = 1.401; 95% confidence
interval [CI] 1.308–1.501; P < 0.001; R2 = 0.597). Adjust-
ment for BMI resulted in no significant changes to the
relationship (OR = 1.396; 95%CI 1.290–1.510;P < 0.001;
R2 = 0.597). Similar results were obtained following
adjustment for BMI, educational level and parity
(OR = 1.400; 95%CI 1.209–1.519;P < 0.001;R2 = 0.612).
According to the results of themultivariate logistic regres-
sion, FLL is significantly correlated with GDM indepen-
dent of BMI, educational level, and parity.
Fetal liver measurements in GDM patients were sig-
nificantly higher than in healthy pregnant women
(P < 0.001; Fig. 2).
The ROC analysis established a cut-off value for FLL
of 39 mm for the prediction GDM, which has a sensitiv-
ity of 71.76%, specificity 97.56%, positive predictive
value 91.0%, and negative predictive value 90.9%. When
tested as a potential prognostic factor for GDM, fetal
liver measurements showed excellent diagnostic perfor-
mance (Table 3). The usefulness of FLL measurements
was supported by a high AUCROC (90.5%). The ability of
the cut-off value of 39 mm for FLL to discriminate
between positive and negative OGTT described by the
ROC statistics is shown in Fig. 3.
Discussion
The present study has demonstrated that there is a highly
significant correlation between FLL and blood glucose
values during an OGTT in patients with GDM. The
nature of the relationship detected implies that FLL may
be a strong predictive factor for OGTT values; this was
confirmed by ROC analysis. Conversely, no such rela-
tionship was found in non-GDM pregnancies.
Ultrasound FLLmeasurements among the non-GDM
subjects in the present study are in agreement with those
reported by Vintzileos et al.18 Furthermore, the signifi-
cantly higher FLL measurements in GDM pregnancies
compared with healthy pregnancies (P < 0.001) in the
present study are in agreement the results of another
study, in which two-dimensional ultrasound was used to
determine liver size.19 A possible explanation for the
positive correlation detected in the present study may be
that maternal hyperglycemia is related to fetal hypergly-
cemia and hyperinsulinemia, which has a significant
impact on the growth of insulin-dependent tissues and
organs, such as the liver.9,10,12
The results of the present study indicate that there is a
positive correlation between FLL and responses to the
Figure 2 Fetal liver length in the gestational diabetes mellitus
(GDM) and non-GDM groups.
Table 3 Diagnostic performance of fetal liver length measurement
in predicting gestational diabetes mellitus
% 95% CI
Sensitivity 71.76 61.0–81.0
Specificity 97.56 94.8–99.1
Positive predictive value 91.0 81.5–96.6
Negative predictive value 90.9 86.8–94.1
Area under the ROC curve 90.5 86.8–93.4
CI, confidence interval; ROC, receiver operating characteristic.
Figure 3 Ability of fetal liver measurements to discriminate
between positive and negative oral glucose tolerance tests, as
described by receiver operating characteristic (ROC) curve (blue line)
statistics using different cut-off levels of fetal liver length.
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OGTT before the test and at each of the three time points
tested after glucose administration. The OGTT is, in
fact, a kind of a physiological test, with blood glucose
levels before the glucose load mimicking fasting blood
glucose levels and blood glucose levels after the glucose
load mimicking levels observed after routine carbohy-
drate intake. Bearing that in mind, the explanation for
the observed correlation may be found in studies that
have shown that maternal fasting and postprandial
blood glucose levels in diabetic pregnancies are corre-
lated with fetal size adjusted for birth weight or gesta-
tional age.20,21 In addition, the results of previous clinical
and experimental studies emphasize the ability of insulin
to stimulate fetal growth and the growth of insulin-
sensitive organs, confirming the hyperglycemia–
hyperinsulinemia hypothesis. Fetal pancreatic β-cell
function in pregnancies complicated by GDM is directly
correlated with maternal glycemia, and fetal size is
directly correlated with fetal insulin production during
the second half of gestation.22 Finally, some authors have
reported that prolonged in utero administration of
insulin in normal fetal monkeys caused substantial
growth of fetal adipose tissue, liver, and heart in the
absence of maternal hyperglycemia.23 Furthermore,
Naeye24 reported that, in post-mortem specimens, the
liver size of fetuses from diabetic mothers was increased
by approximately 80% compared with normal controls
because of both cellular hyperplasia and hypertrophy
and an increased amount of hematopoietic tissue. This
abnormal growth is mostly attributable to fetal hyperin-
sulinemia.25
Although the relationship between FLL and maternal
blood glucose levels during the OGTT appears to be
straightforward, there are several differences between the
GDM and non-GDM subjects that need to be discussed
before final conclusions can be drawn. Specifically, we
found significant differences in the BMI of these two
groups. Although this result was expected, given that
BMI is one of the strongest predictors of GDM, it could
be of great importance in interpretation of the results,
particularly in light of the outcomes of our previous
study,26 in which we investigated the association between
maternal BMI and ultrasound FLL measurements. The
results of that study indicated that maternal BMI was
positively correlated with FLL in the GDM and non-
GDMpopulations,26 although this correlation was stron-
ger in GDM subjects. Therefore, we controlled for this
potential confounder in the present study by using the
moderator model. However, after adjustment for BMI,
no significant changes were obtained for FLL. Accord-
ing to the results of the multivariate logistic regression,
liver length is significantly associated with GDM inde-
pendent of BMI. Similar results were obtained for FLL
after adjusting for BMI, primary school level education,
and secundiparity, meaning that adjustment for poten-
tial confounders does not result in a loss of significance
for the established correlation.
The results regarding the significant difference
between the prevalence of a low level of education in the
GDM and non-GDM groups is surprising. There were
more women with a primary school level of education in
the non-GDM group. Even though low socioeconomic
status has been shown to contribute to the risk of devel-
oping type 2 diabetes, the relationship between GDM
and socioeconomic category is less recognized, with con-
tradictory results observed in previous studies.27,28 Fur-
thermore, little is known about the possible relationship
between maternal educational level, as one of the deter-
minants of socioeconomic status, and GDM.Most prob-
ably in our population there was no direct effect of low
maternal educational level on the increased occurrence
of GDM, which is consistent with the results of Berto-
lotto et al.,27 but in contrast with the findings reported by
Hedderson et al.28 Although the present study does not
address this issue, we think that further research con-
cerning this subject would be of importance for inclusion
or exclusion of low education level as a risk factor for
GDM.
In the second part of the study we investigated the
clinical applicability of the observed correlation and, to
the best of our knowledge, this is the first study to evalu-
ate ultrasound measurements of FLL as a tool for the
prediction of gestational diabetes. We demonstrated that
fetal liver measurements during the mid-trimester ultra-
sound examination can be used to predict GDM in a
high-risk population. Although it has been shown that
fetal liver dimensions have a role in identifying fetal
growth acceleration in diabetic pregnancies, the previous
studies addressed patients with insulin-dependent diabe-
tes mellitus rather than GDM,29 or did not deal with the
diagnostic value of these findings.30 In the study of Boito
et al.,29 liver volumes were evaluated by three-
dimensional ultrasonography. Although probably more
accurate in the evaluation of fetal liver dimensions, this
method is not part of routine pregnancy monitoring, in
contrast with two-dimensional ultrasonography, which
was used in the present study.
Use of the GCT is routinely associated with a sensi-
tivity and specificity of 80% and 90%, respectively, but
positive and negative predictive values fluctuate accord-
ing to the prevalence of GDM in the population tested.31
Therefore, approximately 20% of patients remain undi-
agnosed, even with universal screening. In a recent
review regarding GDM screening tests, it was suggested
that the GCT has a relatively low sensitivity and repro-
ducibility.32 This could be explained by the fact that the
Fetal liver length predicts GDM M. PEROVIC et al.
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GCT results in patients are significantly influenced by the
timing since the last meal. Lewis et al. reported that up to
73% of the population had their test less than 2 h post-
prandially. Exposure to carbohydrates (i.e. the meal)
immediately before the glucose load of the test may
result in enhanced insulin sensitivity and glucose disposal
to the tissues, which may significantly reduce test sensi-
tivity (the Staub–Traugott effect).33 It is important to
stress that, unlike in the GCT, this phenomenon does not
influence fetal liver measurements determined by ultra-
sound examination.
The idea of alternative GDM detection with fetal liver
measurements during routine mid-trimester ultrasound
examination arose from previous studies in which we
demonstrated that GDM could be detected by third-
trimester ultrasound examinations,4,5 as well as other
studies in which earlier screening for the disease was
recommended. Nahum et al.34 suggested that the ideal
period to screen for GDM in high-risk groups is around
16 weeks gestation because of the embryological devel-
opment of fetal β-cells. Each islet cell functions as an
endocrine organ and differentiates between Weeks 10
and 12 of gestation. The cells recognize and respond to
maternal blood glucose before 15 weeks gestation, sug-
gesting that metabolic perturbations take place before
the diagnosis and that earlier screening and intervention
may be needed.35
In the present study we used ROC analysis to make
a decision regarding the cut-off value for FLL in pre-
dicting GDM. With regard to the cut-off value of
39 mm established herein, excellent parameters of valid-
ity were demonstrated, with a sensitivity and specificity
of 71.76% and 97.56% respectively, and positive and
negative predictive values of 91.0% and 90.9%, respec-
tively. The value of these findings is reflected in the fact
that, in the present study, the GDM diagnosis was
made earlier than usual, which is normally between 24
and 28 weeks gestation. This is particularly important
bearing in mind that the prevalence of the disease
increases with pregnancy progression. Seshian et al.36
reported that 22.4% of pregnant women had glucose
intolerance between 17 and 23 weeks gestation, com-
pared with up to 61.3% after 24 weeks. The usefulness
of FLL measurements was supported by a high AUC
(90.5%) during ROC analysis.
One of the major disadvantages of many of the screen-
ing tests used currently is false-positive results. In the
present study, fetal liver measurements demonstrated
better specificity than GCT results based on data in the
literature.31 It is important to stress that, when used in
low-prevalence settings, even excellent tests may have
poor positive predictive values. Our sample included
only women at a high-risk of GDM, which means that
every woman had at least one risk factor for GDM, but
most had a combination of two or more risk factors at
the same time. The prevalence of GDM in our popula-
tion was relatively high (25.7%), which is in accordance
with the results reported by Moses et al.,37 who reported
that the prevalence of GDM in the high-risk population
ranged from 8.5% (among women with only one and the
weakest risk factor for GDM) to 60.8% (among women
who had a combination of risk factors). High prevalence
of the disease in high-risk pregnant women validates the
use of a mid-trimester ultrasound FLL measurement to
detect GDM in a two-step diagnostic approach based on
routine examinations that are performed as part of preg-
nancy monitoring in many countries.
Selection of the high-risk population in the present
study was based only on those factors that are well
known, clearly defined, universally recognized, and
applied in the identification of high-risk populations
worldwide. Accordingly we surveyed pregnant women
representative of the screening population as a whole,
and the survey respondents included relevant groups
from the wider population (general population of preg-
nant women). Therefore, the study sample represents the
population of interest, which is important in terms of
generalizability of the sample, and the results could be
applied in other countries where risk factor-based screen-
ing is performed.
Furthermore, the strategy of screening with the GCT
at 24–28 weeks gestation may not always be a feasible
option in all circumstances because of organizational
reasons and oversights. Even in countries with well-
developed healthcare systems, despite numerous recom-
mendations for GCT screening stipulated in local
guidelines, only one in three pregnant women with risk
factors has been tested using the GCT.38 In contrast, the
mid-trimester ultrasound examination is performed in
almost all pregnant women. Therefore, fetal liver mea-
surement remains a possible additional method for the
detection of GDM because the procedure does not
require a lot of time and effort to obtain the measure-
ments. Furthermore, the GCT is usually performed
between 24 and 28 weeks gestation. Earlier detection of
GDMwith a mid-trimester ultrasound examination may
prolong the time during which a metabolic intervention
could be instituted.
The suggestion that fetal liver measurements during a
mid-trimester ultrasound examination may be predictive
of GDM is attractive, but this finding does require
further evaluation. However, the present study was con-
ducted in pregnant women at 23 weeks gestation. Mid-
trimester scans are usually performed from 18 to 23
weeks gestation. Therefore, the findings of the study are
not applicable in all mid-trimester ultrasound patients.
M. PEROVIC et al. Fetal liver length predicts GDM
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Bearing in mind that the effects of impaired maternal
glucose metabolism on the fetal liver need time to mani-
fest themselves, further studies are needed to confirm or
to refute our findings at earlier than 23 weeks gestation.
Furthermore, as pregnancy progresses, it is known that
there is an increasing likelihood of developing GDM,
which implies that it is likely that affected individuals will
be missed if the screening test is performed early in preg-
nancy. Consequently, using liver measurements made
during the mid-trimester, we would not be able to detect
patients in whom the disease appears during the third
trimester.
The size of our study population was relatively large
and sufficiently powered to observe associations. We
were also very careful in statistical analyses and consid-
ered relevant multivariate models for consistency of find-
ings. These facts could be considered as strengths of the
study. One limitation of the study could be the absence of
any follow-up. Such monitoring after the first, second
and finally third trimester could enable comparison of
the number of women who would be affected by GDM in
each trimester. That way the best timing for early detec-
tion of GDM could be determined exactly. Furthermore,
evaluation of the outcome of pregnancy and clinical
characteristics of a newborn would confirm or refute
more reliably the findings we have detected in utero in
order to verify our conclusions.
In conclusion, in the present study we detected a
strong positive correlation between ultrasound FLL and
OGTT values in GDM patients. The results of ROC
analysis indicate that FLL may even be a strong predic-
tor of GDM. This could imply that fetal liver measure-
ment may be an important addition to conventional
methods in the future early detection of GDM.
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